Parallax Volatility Advisers
UTHR icon

Parallax Volatility Advisers’s United Therapeutics UTHR Stock Holding History

Parallax Volatility Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,000
Closed -$7.06M – 2167
2024
Q4 		$7.06M Buy
+20,000
New +$7.35M 0.01% 693
2024
Q3 		– Sell
-20,000
Closed -$6.37M – 2273
2024
Q2 		$6.37M Buy
+20,000
New +$5.29M 0.01% 630
2017
Q3 		– Sell
-100,000
Closed -$13M – 3335
2017
Q2 		$13M Buy
+100,000
New +$12.5M 0.03% 339
2015
Q3 		– Sell
-4,000
Closed -$696K – 4218
2015
Q2 		$696K Buy
+4,000
New +$720K ﹤0.01% 1486

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Parallax Volatility Advisers's UTHR Position: Q1 2025 in Review

Parallax Volatility Advisers sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 3,344 shares — an estimated $1.18M sold.

Parallax Volatility Advisers first reported a position in UTHR in Q2 2017 and held it in 10 quarters. The position peaked at $5.7M in Q2 2017. 671 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • Parallax Volatility Advisers reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 3,344 United Therapeutics shares in Q1 2025, an estimated $1.18M.
  • Parallax Volatility Advisers first reported a position in United Therapeutics in Q2 2017 and held it in 10 quarters.
  • Parallax Volatility Advisers's United Therapeutics position peaked at $5.7M in Q2 2017.
  • 671 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Parallax Volatility Advisers's 13F filing for Q1 2025, filed 15 May 2025.